Insomnia Chronic

2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
PIMAVANSERINApproved
pimavanserin
Unknown Company
oral

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
1 program
1
PimavanserinPhase 41 trial
Active Trials
NCT04809116Withdrawn0Est. Dec 2023
Verona Pharma
Verona PharmaUK - London
1 program
Digital Health Technology for Chronic InsomniaN/A1 trial
Active Trials
NCT06926348Recruiting50Est. Mar 2026
M&
Merck & Co.RAHWAY, NJ
1 program
lumbar punctureN/A1 trial
Active Trials
NCT04024020Completed30Est. Oct 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acadia PharmaceuticalsPimavanserin
Verona PharmaDigital Health Technology for Chronic Insomnia
Merck & Co.lumbar puncture

Clinical Trials (3)

Total enrollment: 80 patients across 3 trials

Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Start: Dec 2022Est. completion: Dec 20230
Phase 4Withdrawn
NCT06926348Verona PharmaDigital Health Technology for Chronic Insomnia

Assessment of Usability and Preliminary Effectiveness of a Digital Sleep Aid in an Italian Sample

Start: Mar 2025Est. completion: Mar 202650 patients
N/ARecruiting
NCT04024020Merck & Co.lumbar puncture

Chronic Insomnia and CSF Markers of Dementia

Start: Jan 2019Est. completion: Oct 202330 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 80 patients
3 companies competing in this space